WMF 2021 abstract: The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines implicated in COVID-19 disease and is currently being evaluated in the multinational FITE19 Phase 2/3 clinical trial in hospitalized patients

• This Website is intended only for healthcare professionals (“Website“), is operated by PTC Therapeutics. (together with its affiliates “PTC”). In order to access the restricted content on this Website:

  *

  I confirm that I am a licensed healthcare professional and would like to access this Website

  *

  I understand that PTC will process my personal data, including contact details, for the purposes of providing me access to this Website

  I want PTC to provide, by email, updates about new content available to view on MEDhub
• PTC will delete immediately the information provided if we cannot confirm you are healthcare professional.
  Otherwise, in case of successful verification, PTC will retain the information provided for a period of two (2) years two (2) years following your registration (i) only for the purposes of providing you access to this Website; and/or (ii) in case you signed up to receive PTC updates.

Providing your personal data and your consent is voluntary, and you have the right to withdraw your consent at any time, without giving any reasons. Please consult our Privacy Statement for more information on the processing of your personal data.
For any enquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at: Dataprivacy@ptcbio.com.

You can unsubscribe from updates at any time when receiving an email from PTC.